A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 May 2015

At a glance

  • Drugs Evofosfamide (Primary) ; Docetaxel; Gemcitabine; Pemetrexed
  • Indications Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 01 Jul 2014 Results published in a Threshold Pharmaceuticals Media Release.
    • 30 May 2012 Planned end date changed from 1 Aug 2010 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 24 Jan 2011 Updated results from 47 patients with pancreatic cancer were presented at the ASCO Gastro Intestinal Cancers Symposium, according to a Threshold Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top